CCCosmo Pharmaceuticals NV
70.0EURD
−1.0−1.41%
At close at Nov 14, 21:50 GMT
EUR
No trades
Next report date
≈
March 25
Report period
H2 2025
EPS estimate
—
Revenue estimate
—
3.5 EUR
135.00 M EUR
270.31 M EUR
7.13 M
About Cosmo Pharmaceuticals NV
Sector
Industry
CEO
Giovanni di Napoli
Website
Headquarters
Dublin
Founded
2016
ISIN
NL0011832936
FIGI
BBG00CWZRBW1
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
−20%
0%
20%
40%
60%
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
−50.00 M
0.00
50.00 M
100.00 M
150.00 M
Revenue
Net income
Net margin %
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
−20.00 M
0.00
20.00 M
40.00 M
60.00 M
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
−20.00 M
0.00
20.00 M
40.00 M
60.00 M
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
−70.00 M
0.00
70.00 M
140.00 M
210.00 M
Debt
Free cash flow
Cash & equivalents
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
SPISI
UBS ETF (CH) - UBS SPI(R) ESG ETF Units -CHF acc-Weight
0.04%
Market value
820.90 K
USD
SPIA
UBS ETF (CH) - SPI (R) Units -CHF acc-Weight
0.04%
Market value
768.95 K
USD
SPICHA
UBS ETF (CHF) - UBS Core SPI(R) ETF Anteile CHF disWeight
0.04%
Market value
768.95 K
USD
CHSRI
UBS MSCI Switzerland IMI Socially Responsible ETF Units -CHF dis-Weight
0.16%
Market value
535.88 K
USD
CHSRIA
UBS MSCI Switzerland IMI Socially Responsible ETF Units -CHF acc-Weight
0.16%
Market value
535.88 K
USD
Explore more ETFs
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Cosmo Pharmaceuticals NV stocks are traded under the ticker C43.
We've gathered analysts' opinions on Cosmo Pharmaceuticals NV future price: according to them, C43 price has a max estimate of 110.67 EUR and a min estimate of 87.51 EUR. Watch C43 chart and read a more detailed Cosmo Pharmaceuticals NV stock forecast: see what analysts think of Cosmo Pharmaceuticals NV and suggest that you do with its stocks.
Yes, you can track Cosmo Pharmaceuticals NV financials in yearly and quarterly reports right on TradingView.
Cosmo Pharmaceuticals NV is going to release the next earnings report on Mar 25, 2026. Keep track of upcoming events with our Earnings Calendar.
C43 net income for the last half-year is −2.02 M EUR, while the previous report showed 57.47 M EUR of net income which accounts for −103.52% change. Track more Cosmo Pharmaceuticals NV financial stats to get the full picture.
Yes, C43 dividends are paid annually. The last dividend per share was 2.05 EUR. As of today, Dividend Yield (TTM)% is 2.95%. Tracking Cosmo Pharmaceuticals NV dividends might help you take more informed decisions.
As of Nov 16, 2025, the company has 321 employees. See our rating of the largest employees — is Cosmo Pharmaceuticals NV on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cosmo Pharmaceuticals NV EBITDA is 65.06 M EUR, and current EBITDA margin is 59.04%. See more stats in Cosmo Pharmaceuticals NV financial statements.
Like other stocks, C43 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cosmo Pharmaceuticals NV stock right from TradingView charts — choose your broker and connect to your account.